Lipoprotein (a) Inhibits the Generation of Transforming Growth Factor Beta: an Endogenous Inhibitor of Smooth Muscle Cell Migration

Overview

Journal J Cell Biol

Specialty Cell Biology

Date 1991 Jun 1

PMID 1828468

Citations 40

Authors

S Kojima

P C HARPEL

D B Rifkin

Affiliations

Soon will be listed here.

Abstract

Conditioned medium (CM) derived from co-cultures of bovine aortic endothelial cells (BAECs) and bovine smooth muscle cells (BSMCs) contains transforming growth factor-beta (TGF-beta) formed via a plasmin-dependent activation of latent TGF-beta (LTGF beta), which occurs in heterotypic but not in homotypic cultures (Sato, Y., and D. B. Rifkin. 1989. J. Cell Biol. 107: 1199-1205). The TGF-beta formed is able to block the migration of BSMCs or BAECs. We have found that the simultaneous addition to heterotypic culture medium of plasminogen and the atherogenic lipoprotein, lipoprotein (a) (Lp(a)), which contains plasminogen-like kringles, inhibits the activation of LTGF-beta in a dose-dependent manner. The inclusion of LDL in the culture medium did not show such an effect. Control experiments indicated that Lp(a) does not interfere with the basal level of cell migration, the activity of exogenous added TGF-beta, the release of LTGF-beta from cells, the activation of LTGF-beta either by plasmin or by transient acidification, or the activity of plasminogen activator. The addition of Lp(a) to the culture medium decreased the amount of plasmin found in BAECs/BSMCs cultures. Similar results were obtained using CM derived from cocultures of human umbilical vein endothelial cells and human foreskin fibroblasts. These results suggest that Lp(a) can inhibit the activation of LTGF-beta by competing with the binding of plasminogen to cell or matrix surfaces. Therefore, high plasma levels of Lp(a) might enhance smooth muscle cell migration by decreasing the levels of the migration inhibitor TGF-beta thus contributing to generation of the atheromatous lesions.

Citing Articles

Lipoprotein (a)-Related Inflammatory Imbalance: A Novel Horizon for the Development of Atherosclerosis.

Qin T, Ma T, Huang K, Lu S, Zhong J, Li J Curr Atheroscler Rep. 2024; 26(8):383-394.

PMID: 38878139 PMC: 11236888. DOI: 10.1007/s11883-024-01215-5.

Association of Lipoprotein(a) Levels With Myocardial Fibrosis in the Multi-Ethnic Study of Atherosclerosis.

Chehab O, Abdollahi A, Whelton S, Wu C, Ambale-Venkatesh B, Post W J Am Coll Cardiol. 2023; 82(24):2280-2291.

PMID: 38057070 PMC: 11730445. DOI: 10.1016/j.jacc.2023.10.016.

Risk factors and a prediction model for unruptured intracranial aneurysms in patients with ischemic stroke using carotid intima-media thickness and systemic atherosclerosis.

Gao G, Kang D, Zhang J, Jiang Z, He X, Wu Y Front Neurol. 2023; 14:1227673.

PMID: 37706007 PMC: 10495834. DOI: 10.3389/fneur.2023.1227673.

JLP/Foxk1/N-cadherin axis fosters a partial epithelial-mesenchymal transition state in epithelial tubular cells.

Tian M, Zhang L, Zhang M, Qiao L, Xu B, Li C iScience. 2023; 26(4):106396.

PMID: 37013185 PMC: 10066564. DOI: 10.1016/j.isci.2023.106396.

Lipoprotein(a) in Atherosclerotic Diseases: From Pathophysiology to Diagnosis and Treatment.

Lampsas S, Xenou M, Oikonomou E, Pantelidis P, Lysandrou A, Sarantos S Molecules. 2023; 28(3).

PMID: 36770634 PMC: 9918959. DOI: 10.3390/molecules28030969.

References

Kehrl J, Wakefield L, Roberts A, Jakowlew S, Alvarez-Mon M, Derynck R . Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med. 1986; 163(5):1037-50. PMC: 2188095. DOI: 10.1084/jem.163.5.1037. View

Ross R . The pathogenesis of atherosclerosis--an update. N Engl J Med. 1986; 314(8):488-500. DOI: 10.1056/NEJM198602203140806. View

Derynck R, Jarrett J, Chen E, Goeddel D . The murine transforming growth factor-beta precursor. J Biol Chem. 1986; 261(10):4377-9. View

Dennis P, Rifkin D . Cellular activation of latent transforming growth factor beta requires binding to the cation-independent mannose 6-phosphate/insulin-like growth factor type II receptor. Proc Natl Acad Sci U S A. 1991; 88(2):580-4. PMC: 50855. DOI: 10.1073/pnas.88.2.580. View

Lyons R, Keski-Oja J, Moses H . Proteolytic activation of latent transforming growth factor-beta from fibroblast-conditioned medium. J Cell Biol. 1988; 106(5):1659-65. PMC: 2115066. DOI: 10.1083/jcb.106.5.1659. View

Fless G, ZumMallen M, Scanu A . Physicochemical properties of apolipoprotein(a) and lipoprotein(a-) derived from the dissociation of human plasma lipoprotein (a). J Biol Chem. 1986; 261(19):8712-8. View

Miles L, Fless G, Levin E, Scanu A, Plow E . A potential basis for the thrombotic risks associated with lipoprotein(a). Nature. 1989; 339(6222):301-3. DOI: 10.1038/339301a0. View

Rath M, Niendorf A, Reblin T, Dietel M, Krebber H, Beisiegel U . Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis. 1989; 9(5):579-92. DOI: 10.1161/01.atv.9.5.579. View

Sato Y, Rifkin D . Inhibition of endothelial cell movement by pericytes and smooth muscle cells: activation of a latent transforming growth factor-beta 1-like molecule by plasmin during co-culture. J Cell Biol. 1989; 109(1):309-15. PMC: 2115489. DOI: 10.1083/jcb.109.1.309. View

10.

Wakefield L, Smith D, Broz S, Jackson M, Levinson A, Sporn M . Recombinant TGF-beta 1 is synthesized as a two-component latent complex that shares some structural features with the native platelet latent TGF-beta 1 complex. Growth Factors. 1989; 1(3):203-18. DOI: 10.3109/08977198908997997. View

11.

Cushing G, Gaubatz J, Nava M, Burdick B, Bocan T, Guyton J . Quantitation and localization of apolipoproteins [a] and B in coronary artery bypass vein grafts resected at re-operation. Arteriosclerosis. 1989; 9(5):593-603. DOI: 10.1161/01.atv.9.5.593. View

12.

Saunders K, Smith S, DAmore P . An activated form of transforming growth factor beta is produced by cocultures of endothelial cells and pericytes. Proc Natl Acad Sci U S A. 1989; 86(12):4544-8. PMC: 287307. DOI: 10.1073/pnas.86.12.4544. View

13.

Heimark R, Twardzik D, Schwartz S . Inhibition of endothelial regeneration by type-beta transforming growth factor from platelets. Science. 1986; 233(4768):1078-80. DOI: 10.1126/science.3461562. View

14.

McLean J, Tomlinson J, Kuang W, Eaton D, Chen E, Fless G . cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature. 1987; 330(6144):132-7. DOI: 10.1038/330132a0. View

15.

Hajjar K, HARPEL P, Jaffe E, Nachman R . Binding of plasminogen to cultured human endothelial cells. J Biol Chem. 1986; 261(25):11656-62. View

16.

Derynck R, Jarrett J, Chen E, EATON D, Bell J, Assoian R . Human transforming growth factor-beta complementary DNA sequence and expression in normal and transformed cells. Nature. 1985; 316(6030):701-5. DOI: 10.1038/316701a0. View

17.

Niendorf A, Rath M, Wolf K, Peters S, Arps H, Beisiegel U . Morphological detection and quantification of lipoprotein(a) deposition in atheromatous lesions of human aorta and coronary arteries. Virchows Arch A Pathol Anat Histopathol. 1990; 417(2):105-11. DOI: 10.1007/BF02190527. View

18.

Barnard J, Lyons R, Moses H . The cell biology of transforming growth factor beta. Biochim Biophys Acta. 1990; 1032(1):79-87. DOI: 10.1016/0304-419x(90)90013-q. View

19.

Loscalzo J, Weinfeld M, Fless G, Scanu A . Lipoprotein(a), fibrin binding, and plasminogen activation. Arteriosclerosis. 1990; 10(2):240-5. DOI: 10.1161/01.atv.10.2.240. View

20.

Sato Y, Tsuboi R, Lyons R, MOSES H, Rifkin D . Characterization of the activation of latent TGF-beta by co-cultures of endothelial cells and pericytes or smooth muscle cells: a self-regulating system. J Cell Biol. 1990; 111(2):757-63. PMC: 2116212. DOI: 10.1083/jcb.111.2.757. View